Skip to content
AlternativeMed

Dulaglutide: Medicine Overview

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist built as a fusion protein; this overview covers label indications, the REWIND heart trial and main safety information.

Content last updated . This page has not been medically reviewed.

What dulaglutide is

Dulaglutide is a good example of why "peptide" is not one tidy category. The US label describes it as a fusion protein: two identical, disulfide-linked chains, each with a GLP-1 analog sequence joined by a short peptide linker to part of a modified human antibody (IgG4 Fc), made in hamster-cell culture. [1] Its GLP-1 part is 90% homologous to natural GLP-1(7-37). [1] Because of the antibody part, its half-life is about 5 days. [1] Whether you call it a large peptide or a small protein, the useful question is what it was approved for; see peptides vs proteins.

Evidence labels used: approved medicine (a regulator reviewed it for a named use). The brand is Trulicity; dulaglutide is the active ingredient. See active ingredient, brand, formulation and indication.

Formulation

The US label lists Trulicity as a solution in single-dose pens, available in several strengths. [1] Strength and device are part of the product, so they are not interchangeable with other once-weekly products that use a different molecule and device, such as semaglutide pens. Brand, ingredient and form are separate ideas; see the guide linked above.

Mechanism

Dulaglutide activates the GLP-1 receptor on pancreatic beta cells, raising cyclic AMP and glucose-dependent insulin release; it also lowers glucagon secretion and slows gastric emptying. [1] The biology is covered in GLP-1 and GIP biology.

What the trials showed

  • Heart events (REWIND). In a cardiovascular outcomes trial of 9,901 people with type 2 diabetes (4,949 on dulaglutide, 4,952 on placebo), major heart events occurred in 12.0% versus 13.4% (hazard ratio 0.88, interval 0.79 to 0.99). Median follow-up was 5.4 years. [1]
  • Components. Non-fatal stroke was lower (hazard ratio 0.76). Cardiovascular death (0.91) and non-fatal heart attack (0.96) had intervals that included no effect. [1]
  • Children. A 26-week placebo-controlled trial in 154 patients aged 10 and older supports the pediatric diabetes use in the US. [1]
  • Against tirzepatide. Dulaglutide served as the comparison drug in SURPASS-CVOT, where tirzepatide met non-inferiority but superiority was not established. See the tirzepatide overview. [3]

Label: the REWIND result is the main heart evidence, in a type 2 diabetes population only.

Care context

Dulaglutide is prescription-only. Changes in treatment belong with a prescriber, and nothing here is advice to start, stop or switch. For diabetes in general see prediabetes, type 2 diabetes and metabolic syndrome, and for other medicines in the class see metabolic and diabetes peptide medicines.

Frequently asked questions

Is Trulicity the same as Ozempic?

No. Both are once-weekly GLP-1 receptor agonists, but they are different molecules from different companies, each with its own label. [1][4]

Is dulaglutide approved for weight loss?

The US label I read lists blood sugar control and heart-event reduction, not weight reduction. [1]

Did dulaglutide reduce heart attacks?

In REWIND the combined outcome was lower, but the non-fatal heart attack component alone was not clearly different from placebo. [1]

Is it approved for children?

The US label covers type 2 diabetes from age 10, and the EMA page lists patients 10 and older. [1][2]

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

Approved uses (read 2026-10-22)
  • US (FDA label). Improve blood sugar control in adults and children 10 and older with type 2 diabetes; and reduce the risk of major heart events (cardiovascular death, non-fatal heart attack, non-fatal stroke) in adults with type 2 diabetes who have established heart disease or multiple risk factors. [1]
  • EU (EMA page). Patients 10 and older with insufficiently controlled type 2 diabetes, as monotherapy when metformin is unsuitable or alongside other diabetes medicines. [2]
  • Weight. Weight reduction is not among the indications listed on the US label I read. [1]
Main safety information from the label
  • Boxed warning. In male and female rats dulaglutide increased thyroid C-cell tumors; whether it does in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. [1]
  • Common effects. Nausea, diarrhea, vomiting, abdominal pain and decreased appetite (5% or more of people). [1]
  • Warnings list. Pancreatitis (discontinue if suspected), low blood sugar when combined with insulin or sulfonylureas, kidney injury from dehydration, severe stomach and bowel reactions, serious allergic reactions and gallbladder disease. [1]
  • Antibodies. In diabetes trials of 24 to 104 weeks, 64 of 3,907 treated adults (1.6%) developed antibodies against dulaglutide. See immunogenicity of peptide medicines. [1]
  • Pregnancy. Data are limited; animal studies suggest possible fetal risk, and the label says use in pregnancy only if benefit justifies risk. [1]
References
  1. Trulicity (dulaglutide) prescribing information, Eli Lilly, DailyMed listing dated 2026-08-10. Source. Read 2026-10-22.
  2. Trulicity EPAR product page, European Medicines Agency. Source. Read 2026-10-22.
  3. Mounjaro (tirzepatide) prescribing information, Eli Lilly, DailyMed listing dated 2026-09-02. Source. Read 2026-10-22.
  4. Ozempic (semaglutide) injection prescribing information, Novo Nordisk, DailyMed listing dated 2026-06-10. Source. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.